QuidelOrtho Corporation is expanding its QUICKVUE portfolio with the QUICKVUE Influenza + SARS Test, a CLIA-waived, 510(k)–cleared rapid, easy-to-use immunoassay designed for professional use in physician office laboratories, urgent care centers, emergency departments, pharmacies and decentralized hospital labs.
The QUICKVUE Influenza + SARS Test is designed to deliver rapid, simultaneous detection and differentiation of influenza A, influenza B and SARS-CoV-2 antigens from a single patient sample, providing results in as fast as 10 minutes. This capability can help clinicians distinguish between COVID-19 and seasonal flu infections, which present similar symptoms, enabling timely treatment decisions and improved patient outcomes.
Key features and benefits:
- Triple detection capability: Differentiates influenza A/B and COVID-19 in one test.
- Fast results: Clear results available in as fast as 10 minutes at the point of care.
- Professional use: Designed for CLIA-waived and moderate/high-complexity lab settings.
- Efficient workflow: Easy-to-collect nasal swab, streamlined processing and clear result window.
- Affordable access: Cost-effective visual combo test.
Visit QuidelOrtho for more information
